The next-generation ALK inhibitor brigatinib yielded high and durable responses in both whole-body and intracranial endpoints, with a median progression-free survival (PFS) of over 1 year in patients with ALK-positive non-small cell lung cancer (NSCLC) whose disease had progressed after crizotinib, according to the ALTA* trial.
Chronic hepatitis C patients with sustained virological response (SVR) after treatment may still be at risk of hepatocellular carcinoma (HCC), a new study reports. Risk factors include a lower platelet count, cirrhosis and elevated aspartate aminotransferase (AST) levels.
Combined treatment with aspirin and clopidogrel is at least as safe as prolonged aspirin use regarding the risk of cancer, according to a recent study, which supports the hypothesis that clopidogrel use may reduce cancer incidence.
Two Swedish national registry studies presented at the European League Against Rheumatism (EULAR) Annual Congress 2017 suggest no increased cancer risk for rheumatoid arthritis (RA) patients treated with biological disease-modifying anti-rheumatic drugs (bDMARDs), including tumour necrosis factor (TNF) inhibitors.
Obesity is associated with greater risk for unfavourable pathological features in men with low risk prostate cancer who are eligible for active surveillance, according to a study. Obese men are likely to have transition zone cancer, which is related to unfavourable pathology findings in those with very low risk prostate cancer.
The experimental targeted therapy, enasidenib, an oral selective inhibitor of mutated IDH2 enzymesdeveloped for the treatment of acute myeloid leukaemia (AML), has demonstrated maturation of blasts to neutrophils with resultant prolongation of survival in treatment-resistant patients with mutant-IDH2AML in an early trial.
The intravesical installation of Bacillus Calmette-Guerin (BCG) and mitomycin C (MMC) is a safe and effective approach to nonmuscle-invasive bladder cancer (NMIBC) following transurethral resection (TUR), a new systematic review shows.
The oral PARP inhibitor olaparib significantly improved progression-free survival (PFS) in women with BRCA-positive, HER2-negative breast cancer compared with standard chemotherapy in the phase III OlympiAD* trial, ushering in a new era of hope in BRCA-mutated breast cancer.
Colorectal cancer is one of the leading cancers worldwide and one of the most difficult to treat because patients often present in later, metastatic stages of disease. Preventing blood vessel growth is a popular therapeutic strategy to help reduce the proliferation of cancerous tissue. Aflibercept (Zaltrap®, Sanofi) is a monoclonal antibody treatment that targets the cell signalling pathways of angiogenesis to prevent blood vessel growth in malignancies.
Genetically engineered T cells that target and destroy plasma cells may have the potential to cure patients with advanced multiple myeloma (MM), according to the results of a small, phase I/II trial in which one patient with over 90 percent of bone marrow cells affected was cleared of myeloma 1 month after treatment and researchers say he remains in stringent complete remission. [ASH 2015, abstract LBA 1]